Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02845856 2019-09-12

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Phase 1/2 Completed

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00408499 2017-05-08

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Phase 1/2 Completed

64 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00216203 2016-09-29

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Phase 1/2 Completed

36 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00716456 2015-04-30

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Phase 1/2 Completed

21 enrolled 8 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Phase 1/2 Completed

66 enrolled

CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT01166035 2010-07-20

TEXO

Phase 1/2 Unknown

20 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

NCT00034541 2010-04-09

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Phase 1/2 Completed

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

KontRASt-03

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

MK-3475-01F

KontRASt-R

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Study to Evaluate D-1553 in Subjects With Solid Tumors

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

SNK_ASTER

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

TEXO

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer